# A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

> **NCT02138253** · PHASE2 · COMPLETED · sponsor: **Conatus Pharmaceuticals Inc.** · enrollment: 64 (actual)

## Conditions studied

- Liver Fibrosis
- Hepatic Fibrosis
- Liver Cirrhosis
- Hepatic Cirrhosis

## Interventions

- **DRUG:** IDN-6556
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02138253
- **Lead sponsor:** Conatus Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2018-02-15
- **Final completion:** 2018-03-09
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2019-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02138253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02138253, "A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02138253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*